The Food and Drug Administration released briefing documents for Kythera
Biopharmaceuticals Inc.'s (Nasdaq: KYTH) ATX-101 indicating a favorable benefit-risk
assessment. The stock price leaped $10.10 to close at $50.00.
Favorable FDA briefing documents for Kythera's ATX-101
March 05, 2015 at 16:06 PM EST